April 26-29, 2027
Hynes Convention CenterBoston, MA Art Krieg, MDChief Executive Officer at Zola TherapeuticsSpeaker
Profile
Art Krieg, MD founded Zola Therapeutics in 2023, and serves as CEO. Previously Art founded Checkmate Pharmaceuticals, until its acquisition by Regeneron in 2022, RaNA Therapeutics (subsequently Translate Bio, acquired by Sanofi); and Coley Pharmaceutical Group until it’s acquisition by Pfizer in 2008. Art served as CSO of Pfizer’s Oligonucleotide Therapeutics Unit from 2008 to 2011 and co-founded the first antisense journal, Nucleic Acid Therapeutics and the Oligonucleotide Therapeutics Society, for which he recently served as President. He has published more than 250 scientific papers, and is an inventor on >50 issued US patents covering oligonucleotide technologies.
Art Krieg, MD's Network
Agenda Sessions
Activating Anti-tumor Immunity with RNA/DNA Hybrid Agonists of TLR7/8/9
, 4:45pmView Session